A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab. (4th March 2019)

• Record Type: Journal Article
• Authors: Ioannis, Mavroudis; Foivos, Petridis; Dimitrios, Kazis
• Is Part Of: International journal of neuroscience. Volume 129:Number 3(2019)
• Page Start: 297
• Page End: 302
• Publication Date: 2019-03-04
• Subjects: Inclusion body myositis -- Bimagrumab -- Alemtuzumab -- inflammatory myopathies; Nervous system -- Periodicals; 612.805
• DOI: 10.1080/00207454.2018.1527329
• Languages: English
• ISSNs: 0020-7454

Abstract

Abstract: Background : Sporadic inclusion body myositis is the most common inflammatory myopathy over the age of 50. The aetiopathogenesis of the disease remains unclear and to the day there is no effective treatment. Objectives : The aim of the present review is to present the latest data on the new insights and developments in the treatment of sporadic inclusion body myositis, focusing on Bimagrumab and Alemtuzumab. Methods : For the purpose of the review we searched multiple internet databases in order to find the most recent studies and clinical trials on the safety, tolerability and efficacy of Bimagrumab and Alemtuzumab in sporadic inclusion body myositis. Results : We found four trials on Bimagrumab, with one of them being an extension phase III study, and one small series trial on Alemtuzumab. The first clincopathological trial on Bimagrumab showed promising evidence, which were partially confirmed by the double-blinded controlled multicentre trial, however the primary endpoint of improving 6-m walking distance or improving the muscle strength has not been reached. The evidence from the Alemtuzumab trial was also promising, but the risk of bias of the study was relatively high, because it was open labelled, the number of patient was low and the yearly disease progression was much higher than in other recent studies. Conclusions : Although both Bimagrumab and Alemtuzumab were well tolerated and showed promising results, the Bimagrumab trial did not reach the primary endpoint, and the Alemtuzumab trial has a relatively high risk of bias and the results need to be interpreted with caution.